Friday, July 09, 2021 8:29:10 PM
data is being verified and analyzed, and we expect to present top line data towards the end of the third quarter or early part of the fourth quarter of 2021. Through this fibrosis and anti-TNF product development platform, we are also performing research for the development of potential treatments of frozen shoulder, liver and lung fibrosis and POCD.
Recent ATNF News
- 180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 03/14/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 11:03:16 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 09:49:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 01:00:09 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/28/2024 11:42:18 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/28/2024 11:39:40 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/28/2024 11:37:05 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 11:30:47 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:00:18 PM
- 180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan • GlobeNewswire Inc. • 02/26/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 01:01:20 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/16/2024 10:10:53 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/16/2024 10:08:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/16/2024 10:05:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:15:23 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/12/2024 09:15:26 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/31/2024 10:29:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 01:00:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 01:30:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 01:30:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/28/2023 11:42:49 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/27/2023 09:15:23 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/26/2023 09:15:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 10:00:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 01:00:26 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM